Susceptibility to zidovudine and lamivudine was determined on human immunodeficiency virus type 1 (HIV-1) isolates obtained from patients who added lamivudine after 6 months of treatment with zidovudine. Lamivudine-resistant isolates that were also zidovudine-resistant were recovered from 13/16 (81%) patients after 6 months of dual therapy. In contrast to findings in anti-retroviral therapy-naive patients, these results suggest that dual resistance to zidovudine and lamivudine emerges relatively quickly when lamivudine is added to zidovudine as a single agent in the majority of patients with extensive prior zidovudine treatment.
Get full access to this article
View all access options for this article.
References
1.
GaoQ., GuZ., HiscottJ., DionneG., & WainbergM.A.Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2’,3′-dideoxycytidine and 2’,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents & Chemotherapy1993; 37: 130–133
2.
BoucherC.A.B., CammackN., SchipperP., SchuurmanR., RouseP., WainbergM.A., & CameronJ.M.High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents & Chemotherapy1993; 37: 2231–2234
3.
TisdaleM., KempS.D., ParryN.R., & LarderB.A.Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proceedings of the National Academy of Sciences, USA1993; 90: 5653–5656
4.
SchinaziR.F., LloydR.M., NguyenM.H., CannonD.L., McMillanA., IlksoyN., ChuC.K., LiottaD.C., BazmiH.Z., & MellorsJ.W.Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents & Chemotherapy1993; 37: 875–881
5.
EronJ.J., BenoitS.L., JemsekJ., MacArthurR.D., SantanaJ., QuinnJ.B., KuritzkesD.R., FallonM.A., & RubinM. for the North American HIV Working Party. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. New England Journal of Medicine1995; 333: 1662–1669
6.
SchuurmanR., NijhuisM., van LeeuwenR., SchipperP., de JongD., CollisP., DannerS.A., MulderJ., LovedayC., ChristophersonC., KowkS., SninskyJ., & BoucherC.A.B.Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases1995; 171: 1411–1419
7.
LarderB.A., DarbyG., & RichmanD.D.HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science1989; 243: 1731–1734
8.
RichmanD.D., GrimesJ.M., & LagakosS.W.Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. Journal of Acquired Immune Deficiency Syndrome1990; 3: 743–746
9.
LarderB.A., KempS.D.Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science1989; 246: 1155–1158
10.
LarderB.A., KellamP., & KempS.D.Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS1991; 5: 137–144
11.
KellamP., BoucherC.A.B., & LarderB.A.Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Science, USA1992; 89: 1934–1938
12.
BoucherC.A.B., O'SullivanE., MulderJ.W., RamautarsingC., KellamP., DarbyG., LangeJ.M.A., GoudsmitJ., & LarderB.A.Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases1992; 165: 105–110
13.
KatlamaC., IngrandD., LovedayC., ClumeckN., MallolasJ., StaszewskiS., JohnsonM., HillA.M., PearceG., & McDadeH.Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Journal of the American Medical Association1996; 276: 118–125
14.
CAESAR Coordinating Committee.Randomized trial of addition of lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet1997; 349: 1413–1421
15.
LarderB.A., KempS.D., HarriganP.R.Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science1995; 269: 696–699
16.
KuritzkesD.R., QuinnJ.B., BenoitS.L., ShugartsD.L., GriffinA., BakhtiariM., PotichaD., EronJ.J., FallonM.A., & RubinM.Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients. AIDS1996; 10: 975–981
17.
JohnsonV.A., OverbayC.B., KoelJ.L., NailC.D., BartlettJ.A., CammackN., QuinnJ.B., JohnsonJ., KellerA.L., RubinM., & HazelwoodJ.D.Drug resistance, viral load and SI phenotype in NUCA 3002: combined 3TC/ZDV therapy over a maximum of 52 weeks in ZDV-experienced (≤=24 weeks) patients (CD4+ 100–300 cells/mm) [Abstract 58]. Antiviral Therapy1997; 1 (supplement 1): 36–37
18.
GouldenM.G., CammackN., HopewellP.L., PennC.R., & CameronJ.M.Selection in vitro of an HIV-1 variant resistant to both lamivudine (3TC) and zidovudine [letter]. AIDS1996; 10: 101–102
19.
NijhuisM., SchuurmanR., de JongD., VanLeeuwnR., LangJ., DannerS., KeulenW., deGrootT., & BoucherC.A.B.Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases1997; 176: 398–405
20.
JacksonB.J., CoombsR.W., SannerudK., RhameF.S., & BalfourH.H.Rapid and sensitive viral culture method for human immunodeficiency virus type 1. Journal of Clinical Microbiology1988; 26: 1416–1418
21.
JapourA.J., MayersD.L., JohnsonV.A., KuritzkesD.R., BeckettL.A., ArduinoJ.M., LaneJ., BlackR.J., ReichelderferP.S., D'AquilaR.T., & CrumpackerC.S. the RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. A standardized peripheral blood mononuclear cell culture assay for the determination of drug susceptiblities of clinical human immunodeficiency virus-1 (HIV-1) isolates. Antimicrobial Agents & Chemotherapy1993; 37: 1095–1101
22.
KempS.D., KohliA., & LarderB.A.Genotypic characterisation of an HIV-1 mutant co-resistant to AZT and 3TC. Programme & Abstracts of the 4th International Workshop HIV Drug Resistance, Sardinia, Italy, 6–9 July 1995. Abstract 51
23.
KuritzkesD.R., BakhtiariM., ShugartsD.. Resistance to lamivudine (3TC) and zidovudine (ZDV) after prolonged treatment with 3TC/ZDV5th International Workshop on HIV Drug Resistance, Whistler, Canada, 3–6 July 1996. Abstract 57
24.
RusconiS., DePasqualeM.P., MilazzoL., MoscatelliG., BulgheroniE., CitterioP., d'Arminio-MonforteA., MoroniM., & GalliM.Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1 infected patients in an ongoing open-label trial. Antiviral Therapy1997; 2: 39–46
25.
StaszewskiS., LovedayC., PicazoJ.J., DellarnonicaP., SkinhojP., JohnsonM.A., DannerS.A., HarriganP.R., HillA.M., VerityL., & McDadeH.Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. Journal of the American Medical Association1996; 276: 111–117
26.
BartlettJ.A., BenoitS.L., JohnsonV.A., QuinnJ.B., SepulvedaG.E., EhmannW.C., TsoukasC., FallonM.A., SelfP.L., & RubinM. North American HIV Working Party. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine1996; 125: 161–172
27.
WongJ.K., HezarehM., GunthardH.F., HavlirD.V., IgnacioC.C., SpinaC.A., RichmanD.D.Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science1997; 278: 1291–1295
28.
CondraJ.H., HolderD.J., GrahamD.J., ShivaprakashM., LairdD.T., SchleifW.A., ChodakewitzJ.A., & EminiE.A.Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir.International Workshop on HIV Drug Resistance, St Petersburg, Florida, USA 25–28 June 1997. Abstract 47
29.
KempS.D., & BloorS.E.Two distinct mutational pathways in HIV-1 RT confer zidovudine/lamivudine dual resistance.International Workshop on HIV Drug Resistance, St Petersburg, Florida, 25–28 June 1997. Abstract 11
30.
GulickR.M., MellorsJ.W., HavlirD., EronJ.J., GonzalezC., McMahonD., RichmanD.D., ValentineF.T., JonasL., MeibohmA., EminiE.A., & ChodakewitzJ.A.Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine1997; 337: 734–740
31.
CarpenterC.C.J., FischlM.A., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., VolberdingP.A.Antiretroviral therapy for HIV infection in 1997. Journal of the American Medical Association1997; 227: 1962–1969
